FYN proto-oncogene, Src family tyrosine kinase | Src family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

FYN proto-oncogene, Src family tyrosine kinase

Target id: 2026

Nomenclature: FYN proto-oncogene, Src family tyrosine kinase

Abbreviated Name: Fyn

Family: Src family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

   GtoImmuPdb view: ON :     FYN proto-oncogene, Src family tyrosine kinase has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 537 6q21 FYN FYN proto-oncogene, Src family tyrosine kinase
Mouse - 534 10 B1 Fyn Fyn proto-oncogene
Rat - 537 20 q13 Fyn FYN proto-oncogene, Src family tyrosine kinase
Previous and Unofficial Names
FGR | p59-Fyn | SLK | Src Kinase p59 | SYN | FYN oncogene related to SRC, FGR, YES | FYN proto-oncogene
Database Links
BRENDA
CATH/Gene3D
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal Structure of the Human Fyn SH3 domain
PDB Id:  3UA6
Resolution:  1.85Å
Species:  Human
References:  12
Image of receptor 3D structure from RCSB PDB
Description:  Crystal Structure of Fyn kinase domain complexed with staurosporine
PDB Id:  2DQ7
Ligand:  staurosporine
Resolution:  2.8Å
Species:  Human
References:  10
Enzyme Reaction
EC Number: 2.7.10.2

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
acalabrutinib Hs Inhibition <6.0 pEC50 3
pEC50 <6.0 (EC50 >1x10-6 M) [3]
compound 2 [PMID: 15546730] Hs Inhibition 9.0 pIC50 5
pIC50 9.0 (IC50 1x10-9 M) [5]
bosutinib Hs Inhibition 8.7 pIC50 14
pIC50 8.7 (IC50 1.8x10-9 M) [14]
eCF506 Hs Inhibition 8.7 pIC50 7
pIC50 8.7 (IC50 2.1x10-9 M) [7]
PP2 Hs Inhibition 8.3 pIC50 9
pIC50 8.3 (IC50 5x10-9 M) [9]
PP1 Hs Inhibition 8.2 pIC50 9
pIC50 8.2 (IC50 6x10-9 M) [9]
ibrutinib Hs Inhibition 7.5 pIC50 4
pIC50 7.5 (IC50 2.9x10-8 M) [4]
pexmetinib Hs Inhibition 7.4 pIC50 2
pIC50 7.4 (IC50 4.1x10-8 M) [2]
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 6,15

Key to terms and symbols Click column headers to sort
Target used in screen: FYN
Ligand Sp. Type Action Affinity Units
dasatinib Hs Inhibitor Inhibition 9.1 pKd
PD-173955 Hs Inhibitor Inhibition 8.3 pKd
bosutinib Hs Inhibitor Inhibition 8.0 pKd
tamatinib Hs Inhibitor Inhibition 7.6 pKd
staurosporine Hs Inhibitor Inhibition 7.5 pKd
fedratinib Hs Inhibitor Inhibition 7.4 pKd
AST-487 Hs Inhibitor Inhibition 7.3 pKd
lestaurtinib Hs Inhibitor Inhibition 7.1 pKd
foretinib Hs Inhibitor Inhibition 7.1 pKd
masitinib Hs Inhibitor Inhibition 6.8 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx


Reference: 1,8

Key to terms and symbols Click column headers to sort
Target used in screen: Fyn/FYN
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
dasatinib Hs Inhibitor Inhibition 2.0
Lck inhibitor Hs Inhibitor Inhibition 3.5 0.0 0.0
staurosporine Hs Inhibitor Inhibition 3.6 -0.5 -1.0
GSK-3 inhibitor IX Hs Inhibitor Inhibition 5.1 1.0 2.0
TWS119 Hs Inhibitor Inhibition 7.9 0.0 -2.0
indirubin derivative E804 Hs Inhibitor Inhibition 13.0 -1.0 2.0
aminopurvalanol A Hs Inhibitor Inhibition 18.9 9.0 0.0
GSK-3 inhibitor X Hs Inhibitor Inhibition 20.9 1.0 0.0
dorsomorphin Hs Inhibitor Inhibition 20.9 11.0 1.0
dovitinib Hs Inhibitor Inhibition 22.5
Displaying the top 10 most potent ligands  View all ligands in screen »

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S et al.. (2016) Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Res., 76 (16): 4841-4849. [PMID:27287719]

3. Barf TA, Jans CGJM, Man PADeA, Oubrie AA, Raaijmakers HCA, Rewinkel JBM, Sterrenburg J-G, Wijkmans JCHM. (2014) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk inhibitors. Patent number: US20140155385 A1. Assignee: Barf TA, Jans CGJM, Man PADeA, Oubrie AA, Raaijmakers HCA, Rewinkel JBM, Sterrenburg J-G, Wijkmans JCHM. Priority date: 19/07/2011. Publication date: 05/06/2014.

4. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 374 (4): 323-32. [PMID:26641137]

5. Chen P, Norris D, Das J, Spergel SH, Wityak J, Leith L, Zhao R, Chen BC, Pitt S, Pang S et al.. (2004) Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg. Med. Chem. Lett., 14 (24): 6061-6. [PMID:15546730]

6. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

7. Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC et al.. (2016) Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J. Med. Chem., 59 (10): 4697-710. [PMID:27115835]

8. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

9. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem., 271 (2): 695-701. [PMID:8557675]

10. Kinoshita T, Matsubara M, Ishiguro H, Okita K, Tada T. (2006) Structure of human Fyn kinase domain complexed with staurosporine. Biochem. Biophys. Res. Commun., 346 (3): 840-4. [PMID:16782058]

11. Lowell CA. (2004) Src-family kinases: rheostats of immune cell signaling. Mol. Immunol., 41 (6-7): 631-43. [PMID:15220000]

12. Martin-Garcia JM, Luque I, Ruiz-Sanz J, Camara-Artigas A. (2012) The promiscuous binding of the Fyn SH3 domain to a peptide from the NS5A protein. Acta Crystallogr. D Biol. Crystallogr., 68 (Pt 8): 1030-40. [PMID:22868769]

13. Palacios EH, Weiss A. (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene, 23 (48): 7990-8000. [PMID:15489916]

14. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M et al.. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia, 23 (3): 477-85. [PMID:19039322]

15. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

How to cite this page

Src family: FYN proto-oncogene, Src family tyrosine kinase. Last modified on 24/04/2018. Accessed on 16/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2026.